← Changchun High & New Technology Industries overview

Changchun High & New Technology Industries vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Changchun High & New Technology Industries Group Inc (000661.CS)

Q3 202621 Jul – 8 Oct 2026

▲3▼1

Profit Halved, but Drug Pipeline and Global Deal Advance

Interim Profit Halved First-half 2026 net profit fell 51.64% to 475 million yuan as revenue dropped 16.06%. This is the single biggest drag on the stock because it shows the core business is shrinking, even though operating cash flow rose 40.92%.
The profit decline is the main negative force on the stock this period.
Pipeline Wins Keep Coming The company's GeneScience unit won Chinese regulatory acceptance or approval for four new drug candidates: Jintuoximab for gastric cancer, GenSci136 for lupus, GenSci144 for chronic kidney disease, and GenSci133 for osteoporosis. These add future revenue sources, though trials can still fail.
These pipeline advances are the main positive driver and show where future growth may come from.
Osteoporosis Drug Trial Approved GenSci133 injection received clinical trial approval for osteoporosis. It is a long-acting biologic that may be injected only every three to six months, which could make it easier for patients to use and strengthen the company's endocrine and metabolic product line.
This is a concrete regulatory step forward for a key pipeline asset.
Global Rights Deal and New Approval The company is paying $30 million plus up to $70 million in milestones for worldwide rights to Megace, a drug already on China's insurance list. Separately, its leuprorelin injection for prostate cancer received a registration certificate, expanding the marketed product portfolio.
These two events add global reach and a new approved product, supporting future sales.

August 202621 Jul – 8 Oct 2026

▲3▼1

Profit Halved, but Drug Pipeline and Global Deal Advance

Interim Profit Halved First-half 2026 net profit fell 51.64% to 475 million yuan as revenue dropped 16.06%. This is the single biggest drag on the stock because it shows the core business is shrinking, even though operating cash flow rose 40.92%.
The profit decline is the main negative force on the stock this period.
Pipeline Wins Keep Coming The company's GeneScience unit won Chinese regulatory acceptance or approval for four new drug candidates: Jintuoximab for gastric cancer, GenSci136 for lupus, GenSci144 for chronic kidney disease, and GenSci133 for osteoporosis. These add future revenue sources, though trials can still fail.
These pipeline advances are the main positive driver and show where future growth may come from.
Osteoporosis Drug Trial Approved GenSci133 injection received clinical trial approval for osteoporosis. It is a long-acting biologic that may be injected only every three to six months, which could make it easier for patients to use and strengthen the company's endocrine and metabolic product line.
This is a concrete regulatory step forward for a key pipeline asset.
Global Rights Deal and New Approval The company is paying $30 million plus up to $70 million in milestones for worldwide rights to Megace, a drug already on China's insurance list. Separately, its leuprorelin injection for prostate cancer received a registration certificate, expanding the marketed product portfolio.
These two events add global reach and a new approved product, supporting future sales.

Latest21 Jul – 8 Oct 2026

▲3▼1

Profit Halved, but Drug Pipeline and Global Deal Advance

Interim Profit Halved First-half 2026 net profit fell 51.64% to 475 million yuan as revenue dropped 16.06%. This is the single biggest drag on the stock because it shows the core business is shrinking, even though operating cash flow rose 40.92%.
The profit decline is the main negative force on the stock this period.
Pipeline Wins Keep Coming The company's GeneScience unit won Chinese regulatory acceptance or approval for four new drug candidates: Jintuoximab for gastric cancer, GenSci136 for lupus, GenSci144 for chronic kidney disease, and GenSci133 for osteoporosis. These add future revenue sources, though trials can still fail.
These pipeline advances are the main positive driver and show where future growth may come from.
Osteoporosis Drug Trial Approved GenSci133 injection received clinical trial approval for osteoporosis. It is a long-acting biologic that may be injected only every three to six months, which could make it easier for patients to use and strengthen the company's endocrine and metabolic product line.
This is a concrete regulatory step forward for a key pipeline asset.
Global Rights Deal and New Approval The company is paying $30 million plus up to $70 million in milestones for worldwide rights to Megace, a drug already on China's insurance list. Separately, its leuprorelin injection for prostate cancer received a registration certificate, expanding the marketed product portfolio.
These two events add global reach and a new approved product, supporting future sales.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.